Oral second- and third-line lomustine-etoposide-cyclophosphamide chemotherapy for small cell lung cancer

Lung Cancer

Volumn 67, Issue 2, 2010, Pages 188-193

  Lebeau, Bernard ^a   Chouaïd, Christos ^a   Baud, Mariette ^a   Masanès, Marie Josée ^a   Febvre, Michel ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Chemotherapy; Cyclophosphamide; Etoposide; Lomustine; Recurrent disease; Second line therapy; Small cell lung cancer; Third line therapy

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; LOMUSTINE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW HYPOPLASIA; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE INTERVAL; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; HEALTH CARE PLANNING; HOSPITALIZATION; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; SEPSIS; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; HUMANS; LOMUSTINE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SMALL CELL LUNG CARCINOMA;

EID: 72449162122     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.03.024     Document Type: Article

References (41)

1. Spiro S.G., Souhami R.L., Geddes D.M., et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign Trial. Br J Cancer 59 (1989) 578-583
2. Lebeau B., Chastang C., Schuller M.P., et al. Chimiothérapie des cancers à petites cellules. Importance pronostique d'une réponse complète (1280 patients). Presse Med 24 (1995) 217-221
3. Chute J.P., Kelley M.J., Venzon D., et al. Retreatment of patients surviving cancer-free two or more years after initial treatment of small cell lung cancer. Chest 110 (1996) 165-171
4. Huisman C., Postmus P.E., Giaccone G., et al. Second-line chemotherapy and its evaluation in small cell lung cancer. Cancer Treat Rev 25 (1999) 199-206
5. Groen H., Fokkema E., Biesma B., et al. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross resistant schedule. J Clin Oncol 17 (1999) 927-932
6. Joss R.A., Alberto P., Hurny C., et al. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 6 (1995) 41-48
7. Kubota K., Nishiwaki Y., Hojo F., et al. Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer. J Clin Oncol 15 (1997) 292-296
8. Kosmas C., Tsavaris N.B., Malamos N.A., et al. Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer. J Clin Oncol 19 (2001) 119-126
9. Poplin E.A., Aisner J., Van Echo D.A., et al. CCNU, vincristine, methotrexate and procarbazine treatment of relapsed small cell lung carcinoma. Cancer Treat Rep 66 (1982) 1557-1559
10. Hirose T., Horichi N., Ohmori T., et al. Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer. Lung Cancer 40 (2003) 333-338
11. Wolff A.C., Ettinger D.S., Neuberg D., et al. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol 13 (1995) 1615-1622
12. Ettinger D.S., and Lagakos S. Phase III study of CCNU, cyclophosphamide, adriamycin, vincristine, and VP-16 in small-cell carcinoma of the lung. Cancer 49 (1982) 1544-1554
13. Faylona E.A., Loehrer P.J., Ansari R., et al. Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial. J Clin Oncol 13 (1995) 1209-1214
14. Masters G.A., Declerck L., Blanke C., et al. Phase II trial of gemcitabine in refractory or relapsed small cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 21 (2003) 1550-1555
15. Masuda N., Matsui K., Negoro S., et al. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 16 (1998) 3329-3334
16. Huber R.M., Reck M., von Pawel J., et al. Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell cancer. Eur Respir J 27 (2006) 1183-1189
17. Shah C., Ready N., Perry M., et al. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. Lung Cancer 57 (2007) 84-88
18. Onoda S., Masuda N., Seto T., et al. Phase II trial of amrubicin for treatment of refractory or relapsed small cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 24 (2006) 5448-5453
19. Johnson D.H., Greco F.A., Strupp J., et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 8 (1990) 1613-1617
20. Einhorn L.H., Pennington K., and McClean J. Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study. Semin Oncol 17 S2 (1990) 32-35
21. Eckardt J.R., von Pawel J., Pujol J.L., et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small cell lung cancer. J Clin Oncol 25 (2007) 2086-2092
22. Anderson M., Kristjansen P.E., and Hansen H.H. Second-line chemotherapy in small cell lung cancer. Cancer Treat Rev 17 (1990) 427-436
23. Liu G., Franssen E., Fitch M.I., et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15 (1997) 110-115
24. Lebeau B., Chastang C., Allard P., et al. Six vs. twelve cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomized clinical trial. Eur Respir J 5 (1992) 286-290
25. Grunberg S.M., Crowley J., Hande K.R., et al. Treatment of poor-prognosis extensive disease small cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide-a Southwest Oncology Group clinical and pharmacokinetic study. Cancer Chemother Pharmacol 44 (1999) 461-468
26. Lebeau B., Giraud F., Baud M., et al. Lomustine-etoposide-cyclophosphamide for recurrent small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 20 (2001) 281b (abstract)
27. Postmus P.E. Second-line for small cell lung cancer: how to do it?. Lung Cancer 48 (2005) 263-265
28. Murray N. Second-line chemotherapy for small-cell lung cancer. Educationnal Book (2003), ASCO pp. 667-671
29. O'Brien M.E.R., Ciuleanu T.E., Tsekov H., et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small cell lung cancer. J Clin Oncol 24 (2006) 5441-5447
30. Giaccone G., Donadio M., Bonardi G., et al. Tenoposide in the treatment of small cell lung cancer: the influence of prior chemotherapy. J Clin Oncol 6 (1988) 1264-1270
31. Johnson D.H., Greco F.A., Strupp J., et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: a phase II trial. J Clin Oncol 8 (1990) 1613-1617
32. Postmus P.E., Berendsen H.H., van Zandwijk N., et al. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 23 (1987) 1409-1411
33. Sundstrom S., Bremnes R.M., Kaasa S., et al. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatine and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen). Lung Cancer 48 (2005) 251-261
34. Froeschl S., Nicholas G., Gallant V., et al. Outcomes of second-line chemotherapy in patients with relapsed extensive small cell lung cancer. J Thorac Oncol 3 (2008) 163-169
35. de Jong W.K., ten Hacken N.H.T., and Groen H.J.M. Third-line chemotherapy for small cell lung cancer. Lung Cancer 52 (2006) 339-342
36. Clark P.I., Slevin M.L., Joel S.P., et al. A randomized trial of two etoposide schedules in small cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 12 (1994) 1427-1435
37. Park S., Ahn M.J., Ahn J.S., et al. Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer. Lung Cancer 58 (2007) 116-122
38. Rocha Lima C.M., and Chiappori A. Treatment of relapsed small cell lung cancer-a focus on the evolving role of topotecan. Lung Cancer 40 (2003) 229-236
39. von Pawel J., Gatzemeier U., Pujol J.L., et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 19 (2001) 1743-1749
40. Gervais R., Le Guen Y., Le Caer H., et al. Etude de phase 2 randomisée, évaluant une polychimiothérapie orale (CCNU, cyclophosphamide, etoposide) et une polychimiothérapie intraveineuse dans les cancers bronchiques à petites cellules en seconde ligne en rechute (essai GFPC0501). Rev Mal Respir 24 (2007) 653-658
41. von Pawel J., Schiller J.H., Shepherd F.A., et al. Topotecan versus cyclophosphamide, doxorubicin and vincristine for the treatment of recurrent small cell lung cancer. J Clin Oncol 17 (1999) 658-667